A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder
| Autor: | Lee Baer, Cristina Cusin, Richard C. Shelton, Maurizio Fava, Daniel Ju Hyung Kim, Dawn F. Ionescu |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
business.industry media_common.quotation_subject Anger medicine.disease Irritability Placebo behavioral disciplines and activities Crossover study 030227 psychiatry 03 medical and health sciences Iloperidone 0302 clinical medicine mental disorders medicine Major depressive disorder Psychology (miscellaneous) medicine.symptom Psychiatry business Pharmacology Toxicology and Pharmaceutics (miscellaneous) 030217 neurology & neurosurgery Original Research medicine.drug media_common |
| Zdroj: | Therapeutic Advances in Psychopharmacology. 6:4-12 |
| ISSN: | 2045-1261 2045-1253 |
| DOI: | 10.1177/2045125315618621 |
| Popis: | Background: Even when patients experience remission with antidepressants, many continue to report anger attacks and excessive irritability despite continued treatment. Iloperidone antagonizes 5-HT-2a, D2, and alpha-1 receptors, which can have anti-aggressive effects. We examined iloperidone’s safety and efficacy as an augmentation agent in outpatients with partially remitted major depressive disorder (MDD) with residual symptoms of anger and irritability. Methods: A total of 13 outpatients with partially remitted MDD [currently treated with selective serotonin reuptake inhibitors (SSRIs)] received four weeks of iloperidone or placebo, followed by one week of washout. Patients were then crossed over to the other treatment arm for 4 weeks. Treatment arms were randomized and double blind; and two sites were used for the study. Analyses compared treatment response using the Symptom Questionnaire (SQ) Anger/Hostility Subscale as the primary outcome measure. Results: There was no significant differential effect of iloperidone × weeks on the SQ Anger/Hostility Subscore over the course of the study, compared with placebo × weeks, regardless of administration order ( p = 0.77). Conclusions: Iloperidone did not significantly outperform placebo on measures of anger or irritability in patients with partially remitted MDD and residual anger/irritability. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|